Review
Nature Reviews Drug Discovery 7, 241-254 (March 2008) | doi:10.1038/nrd2444
Hormones of the gut–brain axis as targets for the treatment of upper gastrointestinal disorders
Gareth J. Sanger1 & Kevin Lee1 About the authors
Abstract
The concept of the gut forming the centre of an integrated gut–brain–energy axis — modulating appetite, metabolism and digestion — opens up new paradigms for drugs that can tackle multiple symptoms in complex upper gastrointestinal disorders. These include eating disorders, nausea and vomiting, gastroesophageal reflux disease, gastroparesis, dyspepsia and irritable bowel syndrome. The hormones that modulate gastric motility represent targets for gastric prokinetic drugs, and peptides that modify eating behaviours may be targeted to develop drugs that reduce nausea, a currently poorly treated condition. The gut–brain axis may therefore provide a range of therapeutic opportunities that deliver a more holistic treatment of upper gastrointestinal disorders.
- View At a Glance
Author affiliations
- Immuno Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Stevenage, Hertfordshire SG1 2NY, UK.
Correspondence to: Gareth J. Sanger1 Email: gareth_j_sanger@gsk.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transferNature Immunology Article (01 Oct 2001)
See all 22 matches for Research
